...
Authors
Clear selection
...
This website is certified by Health On the Net Foundation. Click to verify.This site complies with the HONcode standard for trustworthy health information:
verify here.
Infliximab And Etanercept Biosimilars And Originators: Learnings From Regional Market Dynamics In Germany

Virtual ISPOR Europe 2020

Conflicts of interests: S.S., I.H. and A.G.V. have founded the KU Leuven Fund on Market Analysis of Biologics and Biosimilars following Loss of Exclusivity (MABEL). S.S. was involved in a stakeholder roundtable on biologics and biosimilars sponsored by Amgen, Pfizer and MSD; he has participated in advisory board meetings for Pfizer and Amgen; he has contributed to studies on biologics and biosimilars for Hospira (together with A.G.V. and I.H.), Celltrion, Mundipharma and Pfizer, and he has had speaking engagements for Amgen and Sandoz. A.G.V. is involved in consulting, advisory work and speaking engagements for a number of companies, a.o. AbbVie, Accord, Amgen, Biogen, EGA, Pfizer/Hospira, Mundipharma, Roche, Sandoz. E.M., T.B.L., G.G., S.E., M.S. and G.S. declare no conflict of interest.